Search

In order to investigate the influence of carbonation treatment on the rebound strength measurement curve of machine-made sand concrete, this study conducted research on the carbonation mechanism sand concrete rebound strength measurement curve through rebound and compressive strength tests using carbonation degree and concrete strength grade as control variables. The results showed that in the short aging period, carbonation treatment had little effect on the compressive strength of manufactured sand concrete but could cause an increase in the rebound value measured by the high-strength and heavy rebound hammers. As the strength grade of the manufactured sand concrete increased, the rebound value measured by both the high-strength and heavy rebound hammers increased accordingly. Compared with the high-strength rebound hammer, the heavy rebound hammer had higher accuracy in detecting the rebound of the carbonated manufactured sand concrete. This study established measurement curves for uncorrected and corrected carbonation depths, among which the accuracy of the corrected carbonation depth measurement curve was higher. At the same time, this measurement curve has been applied to the rebound test of the Pinglu Canal Extra-Large Bridge Project in Guangxi, China, and its practicality and reliability have been verified. [ABSTRACT FROM AUTHOR]

Purpose: The role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear. This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or capecitabine and oxaliplatin (CAPOX) as NAC could improve outcomes in patients with locally advanced colon cancer versus upfront surgery., Patients and Methods: OPTICAL was a randomized, phase III trial in patients with clinically staged locally advanced colon cancer (T3 with extramural spread into the mesocolic fat ≥5 mm or T4). Patients were randomly assigned 1:1 to receive six preoperative cycles of mFOLFOX6 or four cycles of CAPOX, followed by surgery and adjuvant chemotherapy (NAC group), or immediate surgery and the physician's choice of adjuvant chemotherapy (upfront surgery group). The primary end point was 3-year disease-free survival (DFS) assessed in the modified intention-to-treat (mITT) population., Results: Between January 2016 and April 2021, of the 752 patients enrolled, 744 patients were included in the mITT analysis (371 in the NAC group; 373 in the upfront surgery group). At a median follow-up of 48.0 months (IQR, 46.0-50.1), 3-year DFS rates were 82.1% in the NAC group and 77.5% in the upfront surgery group (stratified hazard ratio [HR], 0.74 [95% CI, 0.54 to 1.03]). The R0 resection was achieved in 98% of patients who underwent surgery in both groups. Compared with upfront surgery, NAC resulted in a 7% pathologic complete response rate (pCR), significantly lower rates of advanced tumor staging (pT3-4: 77% v 94%), lymph node metastasis (pN1-2: 31% v 46%), and potentially improved overall survival (stratified HR, 0.44 [95% CI, 0.25 to 0.77])., Conclusion: NAC with mFOLFOX6 or CAPOX did not show a significant DFS benefit. However, this neoadjuvant approach was safe, resulted in substantial pathologic downstaging, and appears to be a viable therapeutic option for locally advanced colon cancer.